This is not good news. One of the most popular drugs of the last two decades coupled with one of the most feared and common cancer diagnoses-Zantac and breast cancer.
According to a 2008 study by a prestigious California-based cancer research institute, those who regularly take Zantac face a 240 percent greater risk of developing ductal carcinoma than those who don’t take the medication, Goldstein’s attorneys said in a lawsuit filed late last month.
Several Zantac breast cancer lawsuits have been filed against the drug manufacturers, 12 years after a peer-reviewed study from the Fred Hutchinson Cancer Research Center linked Zantac with breast cancer.
The study, authored by the American Association for Cancer Research and American Society of Preventive Oncology back in 2008 concluded that the “current use of ranitidine may increase risk of hormone receptor-positive ductal carcinoma,” which is a type of breast cancer. The study found that individuals who regularly took Zantac increased their risk of developing breast cancer by 240% compared to those who didn’t.
Currently, the Sloane Memorial Cancer Center is conducting research to determine which specific cancers Zantac contaminated with NDMA may cause.
Roughly 12 years after the study, in April 2020, the FDA finally pulled ranitidine medicines, including the popular heartburn med Zantac, off the market. Four months earlier, the agency recalled prescription forms of ranitidine by two generic drug companies, bringing the total number of ranitidine recalls to 14 in the past five months, all because of NDMA.
These recalls were a cause of alarm for 15 million people who regularly take prescription Zantac, and concerning to more than 60 million Americans who take the heartburn med at least once a month. Breastcancer.org blogged to its 200,000 members the recalls, adding that the FDA said the levels detected would be “unlikely” to increase the risk of developing cancer. But the FDA is sending mixed messages: it warned on September 13 about the “new studies showing a risk to human health” and that NDMA is a "probable carcinogen in Zantac”. The words “probable” and “unlikely” are not the same…
Now, several breast cancer patients have filed lawsuits against the Zantac drug maker.
We are evaluating Zantac/breast cancer cases right now. We have the best people working for us and have access to the best science on the subject. If you or a loved one contracted breast cancer and took Zantac, please call me for a free initial consultation. We are here to help you in your hour of need.